Navigation Links
Independent Laboratory Testing Shows BioNeutral's Hospital Grade Ygiene(TM) Eliminates Aspergillus Niger (Black Mold) Spores
Date:7/7/2009

NEWARK, N.J., July 7 /PRNewswire-FirstCall/ -- BioNeutral Group, Inc. ("BioNeutral") (OTC Bulletin Board: BONU), a chemical technology-based Life Science company announced today that independent laboratory testing performed by ATS Labs shows that Aspergillus Niger mold spores are completely eliminated by the Company's Ygiene(TM) Hospital Grade antimicrobial in record time.

ATS Labs, using the EPA required Fungicidal Use Dilution test, showed that approximately 2.5 million Aspergillus Niger spores were totally eliminated within two (2) minutes. Aspergillus Niger is a type of black mold spore which is a prolific human heath threatening problem. The spore form of this black mold is particularly difficult to eliminate and total eradication is required in order to alleviate associated health threatening issues.

BioNeutral's Chief Science Officer, Dr. Andy Kielbania, PhD. stated, "These results are particularly important because they both validate our internal lab testing protocols and also confirm the speed, efficacy and power of our Ygiene(TM) antimicrobials. The sporicidal efficacy against Aspergillus Niger (Black Mold) is a key accomplishment for our company." He continued, "These independent lab test results represent a significant achievement. Based upon these results we believe our hospital grade Ygiene(TM) will easily eliminate any health threatening bacteria including very dangerous and difficult to kill antibiotic resistant forms including, Methicillan Resistant Staphylococcus Aureus often referred to as "MRSA", drug resistant Pseudomonas Aeruginosa and the very difficult to eradicate pan resistant Klebsiella Pneumoniae. Obviously the new strain of H1N1 virus (Swine Flu) will not present any problem for our formula to achieve a total Kill in record time."

In an article in Environmental Business International, Inc., The Chelsea Group, an Indoor Air Quality (IAQ) consulting and market research firm, estimates the IAQ market caused by toxic mold to be $2 to $3 billion annually and Anthony Worthan, President and COO of Air Quality Sciences, an IAQ consulting firm in Atlanta, estimates the IAQ market to be growing at an annual rate of 25%.

"These positive independent laboratory results validate that our Hospital Grade formula is now well on its way to becoming the next generation technology in EPA approved disinfectants and sterilants for health care facilities around the world," stated Stephen J. Browand, President and CEO of BioNeutral Group, Inc. "I am confident that our rigorous independent testing program will continue to validate our advanced technology performance with a 100% Total Kill at record speed, while also remaining friendly to people and the environment."

About ATS Labs:

ATS Labs, http://www.ats-labs.com is a leading internationally recognized lab used by the developers and users of antimicrobial products. They provide comprehensive antimicrobial service and their superior client service and scientific data have earned them a distinguished record of acceptance with regulatory agencies in the U.S., Canada and the world.

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene(TM) and Ogiene(TM), which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications.

More information about the Company may be found at www.bioneutralgroup.com

Forward-Looking Statements

BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.

Contact Information

    BioNeutral Group Inc.
    Stephen J. Browand, President and CEO
    steve@bioneutralgroup.com

    Investor Relations
    Aimee Boutcher
    973 239-2878
    aboutcher@aol.com


'/>"/>
SOURCE BioNeutral Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Independent Health to Begin Offering Its Members Vitamins, Supplements and Natural Products
2. New Technology Assists Independent Seniors
3. Helping Dad Stay Independent: The Best Fathers Day Gift for an Aging Parent - A Checklist from Dr. Dan Tobin, Founder and CEO of Care Support of America
4. Three Independent Proxy Advisory Firms Support Stockholder Nominees in Amylin Proxy Fight
5. Support Bristols Highly Qualified Independent Nominees for Advocat Board
6. Gentiva(R) Health Services Receives Nasdaq Notification Regarding Independent Director Requirement
7. Important Data Presented on Independent Predictors of Mortality in Patients With Idiopathic Pulmonary Fibrosis
8. New Organization Formed To Save Independent Medical Equipment Suppliers
9. Super Lice Repelled by All-Natural Products First Ever Independent Study Shows
10. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
11. Vigilan Honors National Nurse Week in Assisted Living, Independent Living and Dementia Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Yorba Linda, Ca (PRWEB) , ... March 29, ... ... a standard process in many scientific laboratories. The assembly protocols involve many repetitive ... is well suited for automation, which enables the high-throughput needed, and results in ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wharton School of the University of Pennsylvania ... have made a $10 million gift to establish the Ken Moelis and Julie ... pathway to a Wharton MBA for highly-qualified Penn undergraduates whose academic and career interests ...
(Date:3/28/2017)... ... March 28, 2017 , ... For many women, getting birth control isn’t as easy as ... they either don’t have access to a health care facility or a pharmacy within 60 ... of the United States or for many who are faced with health or personal issues ...
(Date:3/28/2017)... ... ... The Thyroid Secret is a specialized 9-part documentary series ... recently launched on March 1, and Dr. Wentz discussed varied benefits and aspects ... Wentz is a licensed pharmacist and a foremost thyroid specialist. After being diagnosed ...
(Date:3/28/2017)... ... March 28, 2017 , ... Via Oncology, the leading provider ... a free, public-facing tool for analyzing the costs of various drug regimens in ... information to patients, providers, insurers and pharmaceutical companies about the estimated costs of ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TAIPEI, Taiwan , March 28, 2017 /PRNewswire/ ... medical device company, is pleased to announce ... Series A investment of Panther Orthopedics, Inc., a ... pioneering innovative dynamic fixation solutions for orthopedic extremity ... market continues to expand rapidly, primarily due to ...
(Date:3/28/2017)...  "US Cancer Generics Market Outlook 2022" report ... trend analysis related to the emergence and integration ... in US. The report analyzes various clinical and ... generics drugs in recent years. The introduction of ... dollars for various stake holders involved US cancer ...
(Date:3/28/2017)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today ... and year ended December 31, 2016. ... Orexigen, beginning with the re-acquisition of the rights to ... team at Orexigen demonstrated remarkable focus, executing on a ... our Company while rewarding us full control of our ...
Breaking Medicine Technology: